Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...

FRANKFORT, Ky. (LEX 18) — Governor Andy Beshear signed a proclamation on Tuesday raising awareness for DIPG — diffuse intrinsic pontine glioma — a rare, aggressive brain cancer. This happened as state ...

Dordaviprone targets mitochondrial protease and dopamine receptor D2, representing a novel approach in cancer therapy for H3 K27M-mutant diffuse glioma. The drug application seeks accelerated FDA ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

Vorasidenib is an investigational oral, selective, highly brain-penetrant dual inhibitor of IDH1/2 enzymes. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

These tumors are less likely to spread to surrounding tissues than higher-grade tumors, so they often have better outcomes. In the past, pediatric gliomas were classified into low-grade and high-grade ...

Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and spread of gliomas. An international ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Diffuse intrinsic pontine glioma (DIPG) is an almost universally fatal brain pediatric tumor and the only tumor indication where palliative radiotherapy is the current standard of care. Although ...